• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子对接和分子动力学研究揭示药用植物来源的木脂素作为 MDM2-P53 相互作用抑制剂的抗癌潜力。

Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors.

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan.

Pharmaceutical Care Services, Madinah Cardiac Center, MOH, Al Madinah Al Munawwarah 11176, Saudi Arabia.

出版信息

Molecules. 2023 Sep 16;28(18):6665. doi: 10.3390/molecules28186665.

DOI:10.3390/molecules28186665
PMID:37764441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10536213/
Abstract

The interaction between the tumor suppressor protein p53 and its negative regulator, the MDM2 oncogenic protein, has gained significant attention in cancer drug discovery. In this study, 120 lignans reported from Ferula sinkiangensis and were assessed for docking simulations on the active pocket of the MDM2 crystal structure bound to Nutlin-3a. The docking analysis identified nine compounds with higher docking scores than the co-crystallized reference. Subsequent AMDET profiling revealed satisfactory pharmacokinetic and safety parameters for these natural products. Three compounds, namely, justin A, 6-hydroxy justicidin A, and 6'-hydroxy justicidin B, were selected for further investigation due to their strong binding affinities of -7.526 kcal/mol, -7.438 kcal/mol, and -7.240 kcal/mol, respectively, which surpassed the binding affinity of the reference inhibitor Nutlin-3a (-6.830 kcal/mol). To assess the stability and reliability of the binding of the candidate hits, a molecular dynamics simulation was performed over a duration of 100 ns. Remarkably, the thorough analysis demonstrated that all the hits exhibited stable molecular dynamics profiles. Based on their effective binding to MDM2, favorable pharmacokinetic properties, and molecular dynamics behavior, these compounds represent a promising starting point for further refinement. Nevertheless, it is essential to synthesize the suggested compounds and evaluate their activity through in vitro and in vivo experiments.

摘要

肿瘤抑制蛋白 p53 与其负调节剂 MDM2 致癌蛋白之间的相互作用在癌症药物发现中受到了广泛关注。在这项研究中,对来自新疆阿魏和 的 120 种木脂素进行了对接模拟评估,这些木脂素与 Nutlin-3a 结合的 MDM2 晶体结构的活性口袋上进行了对接模拟。对接分析确定了 9 种化合物的对接评分高于共晶参考物。随后的 AMDET 分析揭示了这些天然产物具有令人满意的药代动力学和安全性参数。由于 Justin A、6-羟基 justicidin A 和 6'-羟基 justicidin B 这三种化合物具有较强的结合亲和力(分别为-7.526 kcal/mol、-7.438 kcal/mol 和-7.240 kcal/mol),超过了参考抑制剂 Nutlin-3a(-6.830 kcal/mol)的结合亲和力,因此选择这三种化合物进行进一步研究。为了评估候选物结合的稳定性和可靠性,进行了 100 ns 的分子动力学模拟。值得注意的是,彻底的分析表明,所有的命中都表现出稳定的分子动力学特性。基于它们与 MDM2 的有效结合、良好的药代动力学特性和分子动力学行为,这些化合物代表了进一步细化的有前途的起点。然而,有必要合成建议的化合物,并通过体外和体内实验评估它们的活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/584883083bd9/molecules-28-06665-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/f0645aefd110/molecules-28-06665-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/2bde13134e21/molecules-28-06665-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/45199977db71/molecules-28-06665-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/862cd4420e91/molecules-28-06665-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/d055682f04e9/molecules-28-06665-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/db3fc6945298/molecules-28-06665-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/d270123678b1/molecules-28-06665-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/1c6ade60564d/molecules-28-06665-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/584883083bd9/molecules-28-06665-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/f0645aefd110/molecules-28-06665-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/2bde13134e21/molecules-28-06665-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/45199977db71/molecules-28-06665-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/862cd4420e91/molecules-28-06665-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/d055682f04e9/molecules-28-06665-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/db3fc6945298/molecules-28-06665-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/d270123678b1/molecules-28-06665-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/1c6ade60564d/molecules-28-06665-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e8/10536213/584883083bd9/molecules-28-06665-g009.jpg

相似文献

1
Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors.分子对接和分子动力学研究揭示药用植物来源的木脂素作为 MDM2-P53 相互作用抑制剂的抗癌潜力。
Molecules. 2023 Sep 16;28(18):6665. doi: 10.3390/molecules28186665.
2
Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study.来自一些药用植物植物化学物质的p53-MDM2二聚化的潜在干扰物:一项分子建模研究
J Biomol Struct Dyn. 2023 Jul-Aug;41(12):5817-5826. doi: 10.1080/07391102.2022.2097313. Epub 2022 Jul 13.
3
Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.整合虚拟筛选和分子动力学模拟揭示了 p53-MDM2 相互作用有前景的药物候选物。
J Mol Model. 2022 May 10;28(6):142. doi: 10.1007/s00894-022-05131-w.
4
Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.提出新型 MDM2 抑制剂:结合物理驱动的高通量虚拟筛选和体外研究。
Chem Biol Drug Des. 2020 Jul;96(1):684-700. doi: 10.1111/cbdd.13694.
5
Target-based virtual screening, computational multiscoring docking and molecular dynamics simulation of small molecules as promising drug candidate affecting kinesin-like protein KIFC1.基于靶点的虚拟筛选、小分子的计算多重打分对接和分子动力学模拟,作为有前途的影响驱动蛋白样蛋白 KIFC1 的药物候选物。
Cell Biochem Funct. 2022 Jul;40(5):451-472. doi: 10.1002/cbf.3707. Epub 2022 Jun 27.
6
Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.美国食品药品监督管理局(FDA)批准的抗HIV蛋白酶抑制剂会成为有前景的抗癌药物吗?基于增强对接方法和分子动力学分析的解答。
Drug Des Devel Ther. 2015 Nov 13;9:6055-65. doi: 10.2147/DDDT.S87653. eCollection 2015.
7
An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.一种综合的计算机筛选策略,用于识别有希望破坏 p53-MDM2 相互作用的化合物。
Comput Biol Chem. 2019 Dec;83:107105. doi: 10.1016/j.compbiolchem.2019.107105. Epub 2019 Aug 16.
8
Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.基于基团的定量构效关系和分子动力学机理分析揭示新型哌啶酮衍生的p53-MDM2蛋白-蛋白抑制剂的作用模式。
J Mol Graph Model. 2014 Jun;51:64-72. doi: 10.1016/j.jmgm.2014.04.015. Epub 2014 May 4.
9
Molecular docking and molecular dynamic simulations of apoptosis proteins with potential anticancer compounds present in extract using gas chromatography-mass spectrometry.采用气相色谱-质谱联用技术对提取物中具有潜在抗癌作用的化合物与凋亡蛋白进行分子对接和分子动力学模拟。
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):6104-6120. doi: 10.1080/07391102.2022.2101530. Epub 2022 Jul 27.
10
Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.模拟 MDM2 N 端结构域在咪唑啉类 MDM2-p53 蛋白-蛋白相互作用抑制剂存在下的构象不稳定性。
J Comput Aided Mol Des. 2020 Jan;34(1):55-70. doi: 10.1007/s10822-019-00260-6. Epub 2019 Nov 28.

引用本文的文献

1
In Silico Identification of Novel Compounds as Anthelmintics Against Through Inhibiting β-Tubulin Isotype 1 and Glutathione S-Transferase.通过抑制β-微管蛋白同种型1和谷胱甘肽S-转移酶在计算机上鉴定新型抗蠕虫化合物
Animals (Basel). 2025 Jun 23;15(13):1846. doi: 10.3390/ani15131846.
2
and analysis of synthesized -benzyl indole-derived hydrazones as potential anti-triple negative breast cancer agents.以及作为潜在抗三阴性乳腺癌药物的合成苄基吲哚衍生腙的分析。
RSC Adv. 2025 Apr 25;15(17):13284-13299. doi: 10.1039/d5ra02194d. eCollection 2025 Apr 22.
3
Bioprospection of metabolites against oxidative stress and inflammation: An and exploration.

本文引用的文献

1
Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.通过靶向酪蛋白激酶 2探索已批准药物治疗三阴性乳腺癌的潜力:计算研究的见解。
PLoS One. 2023 Aug 14;18(8):e0289887. doi: 10.1371/journal.pone.0289887. eCollection 2023.
2
Ethnomedicinal uses, phytochemistry, and pharmacological relevance of Justicia procumbens (Oriental Water Willow) - A promising traditional plant.蔓花生(东方田菁)的民族药用用途、植物化学和药理学相关性——一种很有前途的传统植物。
J Ethnopharmacol. 2023 Dec 5;317:116819. doi: 10.1016/j.jep.2023.116819. Epub 2023 Jun 28.
3
针对氧化应激和炎症的代谢物生物勘探:一项分析与探索。
Int J Med Sci. 2025 Mar 12;22(8):1837-1851. doi: 10.7150/ijms.109116. eCollection 2025.
4
In silico identification of novel ligands targeting stress-related human FKBP5 protein in mental disorders.通过计算机模拟鉴定针对精神疾病中与应激相关的人类FKBP5蛋白的新型配体。
PLoS One. 2025 Mar 17;20(3):e0320017. doi: 10.1371/journal.pone.0320017. eCollection 2025.
5
screening of polyphenols targeting the RhoA protein as a potential liver cancer treatment.筛选靶向RhoA蛋白的多酚类物质作为潜在的肝癌治疗方法。
J Taibah Univ Med Sci. 2025 Feb 13;20(1):89-106. doi: 10.1016/j.jtumed.2025.01.006. eCollection 2025 Feb.
6
Exploring the Pharmacological Potential of Carrageenan Disaccharides as Antitumor Agents: An In Silico Approach.探索角叉菜胶二糖作为抗肿瘤药物的药理潜力:一种计算机模拟方法。
Mar Drugs. 2024 Dec 26;23(1):6. doi: 10.3390/md23010006.
7
Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.调节p53-MDM2信号通路:天然化合物在癌症治疗中的治疗潜力。
EXCLI J. 2024 Nov 22;23:1397-1439. doi: 10.17179/excli2024-7791. eCollection 2024.
8
Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning.基于高斯加速分子动力学模拟和深度学习的肽类和非肽类抑制剂与 MDM2 相互作用机制的研究。
Molecules. 2024 Jul 18;29(14):3377. doi: 10.3390/molecules29143377.
9
Protective effect of kaempferol glucoside against lipopolysaccharide-caused acute lung injury via targeting Nrf2/NF-κB/NLRP3/GSDMD: Integrating experimental and computational studies.山柰酚苷通过靶向Nrf2/NF-κB/NLRP3/GSDMD对脂多糖引起的急性肺损伤的保护作用:整合实验和计算研究
Saudi Pharm J. 2024 Jun;32(6):102073. doi: 10.1016/j.jsps.2024.102073. Epub 2024 Apr 18.
10
Marine-Derived Compounds for CDK5 Inhibition in Cancer: Integrating Multi-Stage Virtual Screening, MM/GBSA Analysis and Molecular Dynamics Investigations.用于癌症中CDK5抑制的海洋来源化合物:整合多阶段虚拟筛选、MM/GBSA分析和分子动力学研究
Metabolites. 2023 Oct 18;13(10):1090. doi: 10.3390/metabo13101090.
Deciphering the pharmacological mechanisms of Rostellularia procumbens (L) Nees. Extract alleviates adriamycin-induced nephropathy in vivo and in vitro.
解析垂序商陆(L)尼氏提取物的药理学机制可减轻体内和体外阿霉素肾病。
Phytomedicine. 2023 May;113:154736. doi: 10.1016/j.phymed.2023.154736. Epub 2023 Mar 1.
4
Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach.通过天然产物抑制 PI3K/AKT/mTOR 信号通路:一种基于计算机的多靶点方法。
SAR QSAR Environ Res. 2023 Feb;34(2):163-182. doi: 10.1080/1062936X.2023.2181392.
5
(Chou-AWei, Chinese ): Traditional Uses, Phytoconstituents, Biosynthesis, and Pharmacological Activities.(周-阿魏,中文):传统用途、植物成分、生物合成及药理活性。
Plants (Basel). 2023 Feb 16;12(4):902. doi: 10.3390/plants12040902.
6
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
7
Antioxidant, Anti-Inflammatory, Anti-Menopausal, and Anti-Cancer Effects of Lignans and Their Metabolites.木脂素及其代谢产物的抗氧化、抗炎、抗更年期和抗癌作用。
Int J Mol Sci. 2022 Dec 7;23(24):15482. doi: 10.3390/ijms232415482.
8
Targeting the omicron variant of SARS-CoV-2 with phytochemicals from Saudi medicinal plants: molecular docking combined with molecular dynamics investigations.针对 SARS-CoV-2 的 omicron 变异株,使用沙特药用植物中的植物化学物质进行靶向治疗:分子对接结合分子动力学研究。
J Biomol Struct Dyn. 2023 Nov;41(19):9732-9744. doi: 10.1080/07391102.2022.2146203. Epub 2022 Nov 11.
9
Role of Natural Products in Developing Novel Anticancer Agents: A Perspective.天然产物在开发新型抗癌药物中的作用:一个视角。
Chem Biodivers. 2022 Nov;19(11):e202200535. doi: 10.1002/cbdv.202200535. Epub 2022 Nov 8.
10
Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.靶向 p53-MDM2 相互作用的小分子抑制剂:从临床试验中的 MDM2 抑制剂中获得的启示。
J Hematol Oncol. 2022 Jul 13;15(1):91. doi: 10.1186/s13045-022-01314-3.